Objectives
In this work, we further investigated the effect of the compound LASSBio‐752 in thrombosis models in rats.
Methods
Arterial and venous thrombosis model, ex‐vivo recalcification time and aPTT and PT.
Key findings
In the venous thrombosis model, oral administration of LASSBio‐752 [48.2 mg (100 μmol)/kg] one hour before the thrombus induction decreased thrombus weight by 37 ± 0.2%. Interestingly, the antithrombotic action of this compound [48.2 mg (100 μmol)/kg] occurred at 87.5 ± 2.1% of inhibition after 24 h of administration and showed a lasting activity. When tested on the arterial thrombosis model, after a 1‐h interval, there was already an increase in time to total occlusion of 34 ± 2.4 min, but the greatest effect was observed at intervals between 6 and 15 h of administration, when no occlusion of the artery was observed. The antithrombotic effect was reduced after 24 h when the occlusion time was 23.8 ± 2.3 min, close to that of the control, 17.6 ± 2.0 min. We also observed that bleeding was not excessive in any of the intervals tested.
Conclusions
Our results indicate that compound LASSBio‐752 is a potential candidate for utilization in the treatment of thromboembolic diseases.